$0.00
−78.05%Price chart
Jul 27Jul 30Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25
Key dataAug 25, 2026
Open$0.23
From 52W high−99.76%
Volume258659.00
Market cap$142481.96
P/E (TTM)—
P/S (TTM)0.1x
Div yield—
Key dataAug 25, 2026
Open
$0.23
From 52W high
−99.76%
Volume
258659.00
Market cap
$142481.96
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
32.4
MomentumView details →
1D Return
−78.05%
YTD Return
−99.04%
SummaryUpdated Jun 1, 2026
Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company founded in 2004 and headquartered in Durham, North Carolina. The company went public in December 2020 and specializes in developing bioengineered human tissues for vascular repair and replacement applications. Humacyte has achieved its first commercial milestone with the FDA approval of its flagship product Symvess in 2024 for treating extremity vascular trauma, marking the transition from a pure research and development company to one generating initial commercial revenues.
Similar companies
Latest newsMore news →
Humacyte, Inc. (HUMA) shares closed at $0.59, up 2.23% from the previous close.2d agoThe U.S. Food and Drug Administration authorized Humacyte to extend the expiration dating period for its Symvess product from 18 months to 36 months when stored refrigerated at 2°C to 8°C.11d agoHumacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.40d ago